Novartis Partners with Gene Editing Co to Boost R&D

Nov 13, 2017

Novartis has entered into a research and development collaboration with Homology Medicines, a genetic medicines company, to develop new treatments for select ophthalmic targets.

In addition to making an upfront payment and equity investment, Novartis will provide funding to advance current programs and to explore new opportunities using the Massachusetts-based startup’s technology platform.

According to Novartis, the collaboration is designed to accelerate an initiative at Novartis Institutes for BioMedical Research (NIBR) that engages researchers across the company who are involved in projects with a common denominator: the genetic reprogramming of cells. Homology’s adeno-associated viruses (AAV) technology may aid their work. 

Read the press release
Read the Novartis article







Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments